Lunbotinib vs Selpercatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline
Lunbotinib
Developed by Ellipses Pharma under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT05443126 (registry estimate)
No aligned efficacy figure on record for this race.
Selpercatinib · Retevmo
Marketed by Eli Lilly and partners
NCT04194944 · Phase 3 · active, not recruiting
LIBRETTO-431 randomised 261 patients with RET fusion-positive NSCLC to selpercatinib or platinum-pemetrexed chemotherapy with or without pembrolizumab. Treatment was open-label, but progression was assessed by blinded independent central review. The primary endpoint, progression-free survival, was met (HR 0.465, 95% CI 0.309 to 0.699, p=0.0002 against chemotherapy plus pembrolizumab); the open-label design keeps the grade at moderate.
Next expected readout: December 2026 · NCT04268550 (registry estimate)
Reported efficacy
Event-Free Survival (EFS) (Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)): Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026) (met)
Result source: NCT04819100
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lunbotinib | Selpercatinib |
|---|---|---|
| PFS, median | —Not reported | 24.8 vs 11.2vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
| OS, median | —Not reported | 33.0NCT04194944 |
| ORR | —Not reported | 83.7% vs 65.1%vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
| Duration of response, median | —Not reported | 24.2 vs 11.5vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
PFS, median
- Lunbotinib
- —Not reported
- Selpercatinib
- 24.8 vs 11.2vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 24.8 vs 11.2 NCT04194944
OS, median
- Lunbotinib
- —Not reported
- Selpercatinib
- 33.0NCT04194944
ORR
- Lunbotinib
- —Not reported
- Selpercatinib
- 83.7% vs 65.1%vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 83.6% vs 62.7% NCT04194944
Duration of response, median
- Lunbotinib
- —Not reported
- Selpercatinib
- 24.2 vs 11.5vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 24.2 vs 12.0 NCT04194944
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lunbotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lunbotinib: 0 of 4 rows · Selpercatinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Selpercatinib |
|---|---|
| Dropout rate | 61.6% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | — NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 34.8% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | aspartate aminotransferase increased 61.4% alanine aminotransferase increased 60.1% hypertension 48.1% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Selpercatinib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lunbotinib's landscape · Selpercatinib's landscape